UPDATE: Bank of America Initiates Akorn at Buy on Product, Revenue Mix
Bank of America initiated coverage on Akorn (NASDAQ: AKRX) with a Buy rating and a $18 price objective.
Bank of America commented, "We like AKRX's mix of niche pharma products in generic injectables and ophthalmology. We also like AKRX's diverse revenue base (generic/brand, Rx/OTC), low product concentration risk (top product contributes ~13% of revenues, vs. ~36% for HITK, IPXL), and targeted ex-US operations (sales and manufacturing), which set AKRX apart vs. its small generic peers. As such, we believe the recent pullback in the shares has created an attractive entry point for investors. While our thesis is based on AKRX as an independent entity, we see the company as an attractive asset in a consolidating generic pharma environment."
Akorn closed at $12.04 on Tuesday.
Latest Ratings for AKRX
|Aug 2016||Deutsche Bank||Downgrades||Buy||Hold|
|Aug 2016||Raymond James||Downgrades||Outperform||Market Perform|
|Mar 2016||Leerink Swann||Maintains||Market Perform|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.